16th world conference on lung cancer † sunday, september 6 ... · i am supposed to say,...

I am supposed to say, “Welcome to Denver!”

I changed my mind.

I would rather say, “Welcome Home!”

It is remarkable that the WCLC takes place in the home city of IASLC. More than just traveling to another

international conference, you are ac-tually travelling home to this monu-mental event, where family members of IASLC will gather and exchange thoughts and ideas. It is at a home event like this that we shall forge new and old relationships and share the fruits of our hard work.

It is also remarkable that this is the fi rst of our annual conferences. Instead of meeting every 2 years as we have been, we shall now meet every year.

This new devel-opment helps to establish WCLC as the premier scientifi c plat-form for sharing the most up-to-date research fi ndings in lung cancer. For exam-ple, at this year’s conference, you will learn about the interesting data from ECOG 1505 on adjuvant bevacizumab, SWOG S0819 on concurrent cetux-imab, whole-exome sequencing on EGFR mutations, and more. This will be a great beginning of our new annual tradition of reviewing the most excit-ing research results at future WCLCs in Vienna in 2016, Yokohama in 2017, and Toronto in 2018.

Most remarkable of all is the fact that you are here. Your presence is import-ant, as we are fi ghting this war togeth-er. Since I gave my inauguration speech on the declaration of war against lung cancer 2 years ago in Sydney, we have taken a few small steps toward victory: the third-generation EGFR tyrosine kinase inhibitor with specifi c effi cacy against the resistant T790M oncogene, the second-generation ALK inhibitor with better central nervous system pen-etration, and the immune-checkpoint therapy with overall survival benefi t are just some examples of marvelous developments that have helped our pa-tients with lung cancer to live longer and better.

Thank you for being here, and thank you for being a member of the IASLC family.

WCLC 2015

NEWSInternational Association for the Study of Lung Cancer

IASLC

16th World Conference on Lung Cancer • Sunday, September 6, 2015 | Denver, Colorado

www.iaslc.org

TODAY’S HIGHLIGHTS

Welcome to WCLC 2015By Fred R. Hirsch, MD, PhD, 2015 Conference President

On behalf of IASLC, I wel-come you to the 2015 Word Conference on Lung Cancer

(WCLC), the premier event for physi-cians and allied health professionals in the fi eld of thoracic malignancies. I am glad you traveled to Denver, the Mile High City, to meet colleagues and share current knowledge and research on the prevention, diagnosis, and mul-tidisciplinary treatment of lung cancer and other thoracic malignancies.

Over the past 2 years, the Local Organizing Committee, led by my co-chairs, James Jett, MD; Harvey Pass, MD; and Everett Vokes, MD, have worked, with the support of the IASLC Board, to create a conference that meets the needs of all conference participants. This year’s conference offers a robust program featuring world-renowned experts and scientif-ic presentations on the latest advances in lung cancer research. Presentations will address all aspects of thoracic malignancies, from tobacco policy to biology to treatment of all stages of lung cancer.

We have created a theme for each day of this year’s conference. These themes refl ect some of the most important is-

sues in lung cancer: prevention and screening, lung cancer in women, and science drives lung cancer advances (eg, personalized medicine). You will fi nd sessions and abstract presentations related to these themes throughout the conference.

As always, a highlight of the WCLC is the Presidential Symposium, which features the four highest ranking ab-stracts. This year’s Presidential Sym-posium includes the best abstracts in biology, prevention, and treatment of lung cancer.

In addition to the Presidential Sym-posium on Wednesday, WCLC 2015 offers a wide variety of invited sessions, Meet the Expert Sessions, and scien-tifi c abstracts presented in Oral, Mini Oral, and Poster Sessions. In addition, we have three Plenary Sessions, one of which focuses on two important IASLC global initiatives: a new proposed inter-national staging system and a new in-ternational pathology classifi ciation.

A unique aspect of the WCLC is its patient-friendliness. We have always encouraged advocates and patients to attend the conference and in fact provide support to advocates with the Advocacy Travel Grants. Our Open-ing Ceremony (today, 19:00-20:30, in Plenary Hall [Bellco Theater]) will also include Emily Bennett Taylor, an

advocate/spokesperson for the Addario Lung Cancer Foundation, and lung cancer survivor.

I also encourage you to visit with our exhibitors in the Exhibit Hall (Hall B + C), where you can learn more about the latest technology and treatments for thoracic malignancies. We thank these exhibitors for their support of the 2015 WCLC.

During your free time, we hope you will explore Denver, a smart, vi-brant city with endless opportunities to sightsee and enjoy great dining (see page 16). We also hope you will enjoy our Gala Dinner on Tuesday night with Kool & The Gang.

Fred R. Hirsch, MD, PhD

James Jett, MD

Welcome from Dr. Mok, IASLC President

INSIDE THIS ISSUE

Awards Presented at Opening Ceremony 2

CT Screening Workshop 4

Spotlight on Advocacy 7

IASLC Mentorship Program 8

Plenary Session to Highlight New Screening, Prevention 9

Vision of New IASLC President-Elect and Board Members 10

History and Growth of IASLC 11

Regulation of Tobacco Products 13

Enjoy the Mile High City 14

Tony Mok, MD

International Thoracic Oncology Nursing Forum Workshop (ticketed session)07:00-11:00Rooms 201 + 203

Pancake Fun WalkSculpture Park, across the street from Colorado Convention Center, Champa and North Speer Blvd.07:30-11:00

Joint IASLC/Chinese Society for Clinical Oncology/Chinese Alliance Against Lung Cancer Session(Simultaneous translation from English to Mandarin provided) 07:30-10:30Mile High Ballroom 1a-1f

Young Investigator and First-Time Attendee Session 07:30-11:00Mile High Ballroom 4a-4f

Workshop: Fact and Myth of Pleural Effusion in Lung Cancer Patients (ticketed session)08:00-11:00Rooms 102 + 104 + 106

Workshop: Contouring for Radiation Treatment Planning of Lung Cancer (ticketed session)09:00-11:00Rooms 601 + 603

Opening Ceremony19:00-20:30Plenary Hall (Bellco Theatre)

Welcome ReceptionExhibit Hall (Hall B + C)IASLC Booth #3715

Harvey Pass, MD Everett Vokes, MD

16th World Conference on Lung Cancer #wclc2015 | www.iaslc.org2

Awards to Be Presented at Opening CeremonySunday’s Opening Ceremony will

feature the presentation of four IASLC Distinguished Awards (see

box at right).

Paul A. Bunn, Jr Scientifi c Award: Dr. Yi-long Wu

Yi-long Wu, MD, is Vice President of the Guangdong General Hospital & Guangdong Academy of Medical Sci-ences, as well as Director of Guang-dong Lung Cancer Institute. Dr. Wu concentrates on increasing lung cancer research in China, which carries a high burden of both tobacco use and lung cancer. He is President of the Chinese Society of Clinical Oncology (CSCO) and focuses on developing CSCO into an international organization. He served as co-chair of the Joint IASLC – Chinese Society for Clinical Oncol-ogy – Chinese Alliance Against Lung Cancer Session that was held Sunday morning. He is also Past Director of the Chinese Society of Lung Cancer; President of the International Chinese Society of Thoracic Surgery; and Pres-ident of the Chinese Thoracic Oncolo-gy Group (C-TONG).

C-TONG’s goal is to design and develop multicenter clinical trials is to provide high-level evidence for the treatment of lung cancer in Chi-na. Working with C-TONG, Dr. Wu played a key role in more than 30 phase

I-IV clinical trials and translational re-search launched since the group was formed in 2007. Most of the trials are biomarker-guided, such as the IPASS and OPTIMAL trials, which helped establish gefi tinib and erlotinib as fi rst-line therapy for lung cancer. Dr. Wu’s research interest is profi ling the lung cancer tumors in Chinese patients for driver oncogenes and to build a tumor tissue bank across hospitals in China, connected by a computer system.

“Dr. Wu is a leader in lung cancer and has contributed signifi cantly by introducing modern therapies for lung cancer in China and other parts of Asia,” says Fred R. Hirsch, MD, PhD, IASLC CEO, and Professor of Medi-cine and Pathology at the University of Colorado, Denver, USA.

Dr. Wu has been extensively involved with IASLC, serving on the Board of Directors since 2013, and he is current-ly the Board liaison to the IASLC Stag-ing Committee. He is also a member of the American Society of Clinical On-cology’s (ASCO’s) International Affairs Committee.

Dr. Wu earned his medical degree from Sun Yat-sen University and com-pleted thoracic surgery training in Ger-many. He is a Fellow of the American College of Surgeons.

IASLC Merit Award: Dr. Harvey Pass

Harvey Pass, MD, is Vice Chair for Research in the Department of Cardio-thoracic Surgery at New York Univer-sity Langone Medical Center, as well as the Stephen E. Banner Professor of Thoracic Oncology. He enjoys a long history of service for IASLC, as-suming many roles since he joined in 1995, including member of IASLC’s Scientifi c Program Committee since 2001; IASLC’s Board of Directors 2005-2009; Chair of the Publications Committee since 2013; and Co-Chair of this year’s WCLC. In addition, he developed courses for the 2014 Best of the WCLC; served as Associate Editor for the Journal of Thoracic Oncology from 2005-2009, and served as Executive Ed-itor of the IASLC textbook, The IASLC Multidisciplinary Approach to Thoracic Oncology.

“IASLC is grateful for Dr. Pass’ ed-itorship of the most comprehensive textbook on thoracic malignancies,” Dr. Hirsch says. “His contributions to gaining a better understanding of the biology and biomarkers for thoracic malignancies are unique and unusual for a surgeon. He has trained many of the next generation of leading thoracic surgeons and is considered a ‘godfa-ther’ in the fi eld of thoracic surgery.”

Dr. Pass earned his medical degree from Duke University and served as the

Chief Resident, General Surgery, at the University of Mississippi Medical Cen-ter, Jackson, and as the Chief Resident, Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston. He then was a Senior Staff Fellow, Thoracic Oncology Section, Surgery Branch, at the National Can-cer Institute. He served as the Chief of Thoracic Oncology for the Surgery Branch, National Cancer Institute from 1986-1996, and was the Chief of Thoracic Oncology at the Karmanos Cancer Institute in Detroit until he moved to the NYU Langone Medical Center in 2005.

In addition to his editorial work for IASLC, he has served as an editori-al board member for several oncology journals. He held an appointment as the NCI representative on the Ameri-can Joint Commission on Cancer 1991-1996, and Surgical Chair for the Lung Cancer Committee, Radiation Therapy Oncology Group, 2004-2010. He has been a member of the American Associ-ation for Cancer Research (AACR) since 2002; and was Chair of the Lung Cancer Alliance Medical Advisory Board from 2005-2009, and a member of its Board of Directors from 2006-2009.

Dr. Pass is the principal investigator or co-investigator for several NIH/NCI grants, including the in silico identifi cation and experimental verifi -cation of candidate cancer biomarkers based on “-omics”; the Chilean-Amer-ican mesothelioma biomarker project; the North American mesothelioma consortium; Identifying non-coding RNAs for early detection and preven-tion of lung cancer; and Networks of tissue source site (TSS) in support of the TCGA whole genome sequenc-ing for non-small cell lung cancer. He holds several active patent applications in relation to mesothelioma and asbes-tos exposure.

He has won awards from the Addario Lung Cancer Foundation, Mesothe-lioma Applied Research Foundation, AACR, New York University, and many other organizations.

Joseph W. Cullen Prevention/Early Detection Award: Dr. Jacek Jassem

Jacek Jassem, MD, PhD, is a Profes-sor of Clinical Oncology and Radio-therapy and Head of the Department of Oncology and Radiotherapy at the Medical University of Gda ́nsk, Poland. The department’s research unit focus-es on clinical trials and translational research combining cancer molecular features with clinical behavior. The team has developed and validated novel tumor biomarkers in lung cancer and breast cancer, and shares a long-term collaboration with University of Colo-rado, publishing in the fi eld of predic-tive assays for the benefi t from targeted therapies in lung cancer.

Dr. Jassem is past chair of the Eu-ropean Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Group and the EORTC Ex-ecutive Committee, past chair of the Central and East European Oncology Group, past chair of ASCO‘s Interna-tional Affairs Committee, and the Im-mediate Past President of the Polish Oncological Society. He is a member of the European Academy of Cancer Sciences, the Polish Academy of Art and Sciences, and the European So-ciety for Medical Oncology (ESMO) Executive Board.

Professor Jassem received his MD and PhD degrees from the Medical University of Gda ́nsk, Poland. He then trained in oncology at the Kar-olinska Institute in Stockholm and National Cancer Institute in Amster-dam. He made contributions to sev-eral radio and TV programs and arti-cles in lay press on the role of science in the development of public health and oncology, and is a coauthor of several educational fi lms addressing these topics. He has been instrumen-tal in several anti-tobacco campaigns in Poland and authored anti-tobacco legislation introduced by the Polish Parliament in 2010. He is a recipient

see Awards, page 9

2015 IASLC Distinguished Awards

Yi-Long Wu, MDPaul A. Bunn, Jr. Scientifi c Award

Harvey Pass, MDIASLC Merit Award

Jacek Jassem, MD, PhDJoseph W. Cullen Prevention/Early Detection Award

Ming Tsao, MD, FRCPCMary J. Matthews Pathology/Translational Research Award

Opening Ceremony Today

All WCLC delegates are invited to attend today’s Opening Ceremony19:00-20:30Plenary Hall (Bellco Theater)

WelcomesFred R. Hirsch, MD, PhD, IASLC CEO and WCLC 2015 PresidentTony Mok, MD, IASLC President

Presentation of Distinguished Awards (see article above)

Exciting News about New Funding Opportunities

Voice of a Patient AdvocateEmily Bennett Taylor, lung cancer survivor

EntertainmentGrass It Up, critically acclaimed Colorado-based bandNative American dancers

#wclc2015 | www.iaslc.org Sunday, September 6, 2015 | Denver, Colorado 3

To learn more about OPDIVO, visit booth 1617

OPDIVO® and the related logo are trademarks of Bristol-Myers Squibb Company. ©2015 Bristol-Myers Squibb Company. All rights reserved. Printed in USA. 1506US15BR00841-03-01 06/15 For U.S. Healthcare Professionals Only

2015 Lectureship Awards

The IASLC has recognized six in-vestigators with 2015 Lectureship Awards for their high-ranking ab-

stracts in key areas of lung cancer. These awards are named after IASLC members who have been leaders in the areas of pa-thology, surgery, small cell lung cancer, medical oncology, and staging. The win-ners will receive their awards before their presentations in Oral Abstract Sessions.

Adi Gazdar Lectureship Award (Translational Research)Adi Gazdar, MD, is the W. Ray Wallace Distinguished Chair, Molecular Oncology Research, Hamon Center for Therapeutic Oncology, Pathology, UT Southwestern Medical Center, Houston, Texas. As Head of the Tumor Cell Biology Section at the Na-tional Cancer Institute, Dr. Gazdar collected, catalogued, and analyzed more than 2,200 human cancer specimens, mostly lung cancers and lymphomas. He was honored with the IASLC Mary Matthews Pathology/Translational Research Award in 2003.

2015 Recipient: Lynnette Fernandez-Cuesta, PhDInternational Agency for Research on Cancer (IARC-WHO), Lyon, France

“Genomic Characterization of Large-Cell Neuroendocrine Lung Tumors”Oral Session 06: Next Generation Sequencing and Testing Implications Monday, September 7; 10:45-12:15Mile High Ballroom 1a-1f

Robert Ginsberg Lectureship Award (Surgery)Robert J. Ginsberg, MD, was a leading thoracic surgeon and founding member of the General Thoracic Surgical Club. Dr. Ginsberg served as Chief of Thoracic Surgery at Toronto Western Hospital, Canada; Memorial Sloan Kettering Cancer Center, New York, New York; and University of Toronto. He was honored with the IASLC Scientifi c Award in 1994. He died of lung cancer in 2003.

2015 Recipient: Virginie Westeel, MDCentre Hospitalier Universitaire, Besançon, France“Compliance with Follow-Up Programs after Surgery for Non-Small Cell Lung Cancer in the Phase III IFCT-0302 Trial”Oral Session 34: Quality/Survival/Prognosis in Localized Lung Cancer Wednesday, September 9; 16:45-18:15 Rooms 201 + 203

Heine Hansen Lectureship Award (Small Cell Lung Cancer)Heine H. Hansen was a founding mem-ber of IASLC and served as its President (1988-1991) as well as its Executive Di-rector (1994-2003). He was awarded the IASLC Merit Award in 1997. His lifelong clinical interest was the treatment of small cell lung cancer. He died in 2011.

2015 Recipient: Charles Rudin, MD, PhDMemorial Sloan Kettering Cancer Center, New York, New York“A DLL3-Targeted ADC, Rovalpituzumab Tesirine, Demonstrates Substantial Activity in a Phase I Study in Relapsed and Refractory SCLC”Oral Session 10: SCLCMonday, September 7; 10:45-12:15Rooms 605 + 607

Dan Idhe Lectureship Award (Medical Oncology)The award is named after Daniel C. Ihde, MD, who served as Deputy Director of the National Cancer Institute, Bethesda, Maryland, followed by appointments at Washington University School of Med-icine, St. Louis, Missouri, and at H. Lee Moffi tt Cancer Center, Tampa, Florida. Dr. Ihde was one of the fi rst oncologists to show that combination therapy could help people with small cell lung cancer, and

he was honored with the IASLC Scientifi c Award in 1997. Dr. Ihde died in 2004.

2015 Recipient: John Edwards, MDNorthern General Hospital, Sheffi eld, UK“Quality of Resection in Pathological N2 NSCLC in the Phase 3 Lung Adjuvant Radiotherapy Trial (Lung ART): An Important Factor”Oral Session 05: SurgeryMonday, September 7; 10:45-12:15Rooms 201 + 203

Clifton Mountain Lectureship Award (Staging)Clifton Mountain, MD, was a founding member of IASLC and served as its Pres-ident 1977-1978 and led the plans for the fi rst WCLC in 1978. He was the recipient of the fi rst IASLC Merit Award in 1991. Dr. Mountain contributed signifi cantly to the TNM staging system, particularly in non-small cell lung cancer.

2015 Recipient: Edward Robbins, MDBaptist Cancer Center, Multidisciplinary Thoracic Oncology Program, Tennessee, US“Evolution in the Surgical Care of Non-Small Cell Lung Cancer (NSCLC) Patients in the Mid-South Quality of Surgical Resection (MS-QSR) Cohort”

see Lectureship Awards, page 5


Saturday Workshop Examined Promises, Challenges to Implementation of CT Screening Programs Around the World

International leaders in computed to-mography (CT) screening from across the globe, including Japan, Australia,

Canada, Europe, and the United States, participated in the IASLC’s Strate-gic Screening Advisory Committee’s (SSAC) Third CT Screening Work-shop on Saturday. The all-day, sold-out workshop offered an opportunity for experts to share current advances in lung cancer screening and provided a forum where they could discuss and debate the issues and barriers to setting up lung cancer screening programs in regions outside of the United States.

CT screening is more important than ever, as the World Health Organization reports that lung cancer accounted for the most cancer-related deaths in 2012, with nearly 1.6 million people dying of the disease that year.

“In light of the emerging internation-al evidence and the commitment from the US government to cover the cost of lung cancer screening in the high-risk population, there is rapidly growing interest in all aspects of this new ap-proach to early lung cancer detection,” said James L. Mulshine, MD, Acting Dean of The Graduate College of Rush University Medical Center, Chicago, Illinois, and one of the members of the workshop’s organization committee.

“Effi cient screening may save thou-sands of lives and must be implement-ed around the globe,” added Nir Peled, MD, PhD, Chair of the IASLC Preven-tion, Screening, and Early Detection Committee and head of the Thoracic Cancer Unit, Davidoff Cancer Center, Tel Aviv University, Israel.

Professor John K. Field, Chair of the IASLC SSAC CT screening workshop, echoed the importance of progress with CT screening. “It is imperative that we take this initiative forward interna-tionally, as CT screening is the only currently approved method we have

available to reduce the burden of lung cancer, alongside an integrated tobacco control program,” said Professor Field, who is the Director of Research, Roy Castle Lung Cancer Research Pro-gramme, The University of Liverpool Cancer Research Centre, Liverpool, United Kingdom.

Highlights of the ProgramThe workshop comprised three sep-

arate sessions followed by a roundtable discussion. Session 1 addressed major advances in lung cancer screening, in particular, the new CT-screened nodule guidelines from the NELSON trial and also those from the British Thoracic So-ciety; quality control for future screen-ing programs; and cost-effectiveness and patient selection, using risk-pre-diction modeling, for future programs. Session 2 was devoted to a discussion of validated biomarkers of early disease, such as microRNA and bronchial air-way expression, which may be of value to clinical investigators as they seek to identify high-risk subgroups for inclu-sion in future CT screening demonstra-tion projects. In Session 3, participants discussed the status of their countries’ plans for implementing lung cancer CT screening and talked about barriers that are interfering with CT screening efforts. In the United States, consensus is lacking about how best to move for-ward with implementing CT screening, which generated a robust discussion.

Participants in the roundtable dis-

cussion worked to formulate IASLC recommendations to assist nation-al health services outside the United States to imple-ment lung cancer screening pro-grams. The emer-

gence of CT lung cancer screening as a public health tool provoked a lively global debate with regard to its potential merits and the best path to implemen-tation. Nevertheless, workshop partic-ipants agreed that there was consensus that while this healthy debate should continue, potentially unprecedented op-portunities exist with this new approach to early lung cancer detection that merit serious international consideration.

“IASLC is a great forum to explore the complex issues of CT screening and work toward consensus. All IASLC members share the vision of the associ-ation to advance progress in reducing the burden of lung cancer, so we are pleased with the very productive ex-change of ideas at the workshop,” Dr. Mulshine said.

The consensus from the workshop will be published as “The IASLC SSAC International Recommendations for Lung Cancer Screening.”

Challenges in Implementing Screening

Before the workshop, Dr. Mulshine discussed the profound challenge of implementing national CT screening to ensure delivery of high-quality, early lung cancer detection that is driven by best practices and delivered to the target population of tobacco-exposed individ-uals. He noted that in the United States, advocacy groups are working with aca-demic medical centers and community hospitals to address this challenge by

creating a consortium of institutions that conduct screening programs to systematically adopt best standards of screening practice for all components of the clinical management of lung cancer. For example, the Lung Cancer Alliance launched the National Framework of Excellence in Lung Cancer Screening and Continuum of Care in February 2012, with goals of providing guidance to lung cancer screening programs about how to set up and implement responsi-ble, high-quality screening programs; encouraging collaborative research for

improving early detection in lung can-cer and to identify other high-risk pop-ulations meeting these criteria; and edu-cating the public about their lung cancer risk and to ensure equitable access to the service. The Alliance has built a network of more than 350 Screening Centers of Excellence across the country that are committed to responsible, high-quality screening practices.

The workshop was developed under the di-rection of the IASLC Prevention, Screen-ing and Early Detection Committee. The Organizing Committee for the workshop includes Dr. Peled; Professor Field; Dr. Mulshine; Denise Aberle, MD, Los An-geles, California; Matthijs Oudkerk, MD, Groningen, The Netherlands; Annette McWilliams, Perth, Australia; and Mo-toyasu Sagawa, Ishikawa, Japan.

Nir Peled, MD, PhDJames L. Mulshine, MD

IASLC is a great forum to explore the complex issues of CT screening and work toward consensus.”

James L. Mulshine, MD

Welcome from Denver MayorMichael B. Hancock, Mayor of Denver

Welcome to the Mile High City! Denver is honored to host the 16th World Con-

ference on Lung Cancer. I invite you to explore our city and

experience all it has to offer. From seven pro sports teams to the nation’s second-largest performing arts com-plex and the mile-long 16th Street Mall to our many museums and

cultural facilities, Denver is fi lled with attractions to entertain you.

Our many neighborhoods like Cherry Creek, Highlands, LoDo, Uptown, Five Points, Golden Tri-angle, and Old South Pearl are fi lled with outstanding restaurants and one-of-a-kind shops, while af-ter dark, Denver is a center for live music. Whether you visit one of our

parks like Red Rocks Park and Am-phitheatre or borrow a B-cycle and take a bike ride on our 850 miles of off- street bike paths, you’ll fi nd that Denver has 300 days of bright sun-shine a year.

At an elevation of 5,280 feet above sea level, Denver is truly a mile high… and climbing. Have a wonderful con-ference and enjoy your stay!

Co

urte

sy o

f Den

ver

May

or’s

Offi

ce

Prof. John K. Field


Join IASLC for a special Welcome Reception

after the Opening Ceremony. Network with

colleagues and friends and visit exhibitors while

enjoying local wines and exquisite canapés.

Welcome Reception Today» 20:30-21:30

IASLC Booth (#3715) Exhibit Hall (Hall B+C)

Free with full registration;

additional tickets for guests

can be purchased onsite.

Dress Code: Business Casual

Fellowship Awards

T en young researchers have re-ceived IASLC Fellowship Awards, which are designed to

recognize scientifi c excellence and to encourage innovative research in lung cancer prevention and translational medicine worldwide. The awards com-prise 1-year Fellowship Awards, Young Investigator Awards, and the Chinese Lung Cancer Fellowship Award.

The IASLC collaborated with Boehringer Ingelheim on the Chi-nese Lung Cancer Fellowship Award, which enables a fellow to come to the United States for a 1-year research project. The goal of this fellowship is to encourage innovative and col-laborative investigation in the fi elds of lung cancer prevention, diagnosis, and translational research with a po-tential impact on the management of lung cancer.

The other 2015 Fellowship Awards are supported by AstraZeneca, Bris-tol-Myers Squibb, Celgene, Daiichi Sankyo, Eli Lilly, Genentech, Pfi zer, and the Prevent Cancer Foundation.Applications for Fellowship and Young Investigator awards are accepted each January.

Applications are evaluated by the IASLC Fellowship Committee for their merit, innovation, and poten-tial impact on the management of lung cancer. To learn more about the awards, visit https://www.iaslc.org/fellowship.

2015-2016 Fellowship Awards• Puey Ling Chia, MBBS, MRCP,

Victoria, AustraliaDr. Chia will study under the mentorship of Professor Thomas John, MBBS, FRACP, PhD, at The Austin Hospital, Victoria, Australia.

• Colin Lindsay, PhD, Paris, FranceDr. Lindsay will study under the mentorship of Dr. Benjamin Besse, at Institut Gustave-Roussy, Paris, France.

• Yoichiro Mitsuishi, MD, PhD, Boston, MassachusettsDr. Mitshushi will study under the mentorship of Matthew Meyerson, MD, PhD, at Dana-Farber Cancer Institute.

• Sara Pilotto, MD, Verona, ItalyDr. Pilotto will study under the mentorship of Prof. Emilio Bria, MD, G.B. Rossi Academic Hospital at the University of Verona. Italy

• Adrian Sacher, MD, Boston, MassachusettsDr. Sacher will study under the mentorship of Geoffrey R. Oxnard, MD, at Dana-Farber Cancer Institute.

2015-2016 Young Investigator Awards• Mark M. Awad, MD, PhD

Harvard Medical School and Dana-Farber Cancer Institute, Boston, Massachusetts

• Jill Larsen, PhDQIMR Berghofer Medical Research Institute, Brisbane, Australia

• Kenichi Suda, MDDivision of Thoracic Surgery, Kinki University Faculty of Medicine, Osaka-Sayama, Japan

• Silvestre Vincent, PhDCenter for Applied Medical Research, Pamplona, Spain

2014-2016 IASLC/Boehringer Ingelheim Chinese Research Fellowship Award • Yayi He, Shanghai Pulmonary

Hospital, ChinaDr. He will conduct her research fellowship at the University of Colorado Anschutz Medical Campus under the guidance of Fred R. Hirsch, MD, PhD.

Oral Session 30: Community Practice Tuesday, September 8; 16:45-18:15Mile High Ballroom 2c-3c

Tsuguo Naruke Lectureship Award (Surgery)Tsuguo Naruke introduced the concept of lymph node mapping, and his work was the foundation for the classifi cation of regional lymph node stations by the American Joint Committee on Cancer and the Union Internationale Contre le Cancer. Working in the Department of Thoracic Surgery, Saiseikai Central Hospital, Tokyo, Japan, Dr. Naruke was also involved in studies of video-assisted thoracic surgery in lung cancer. He died in 2006.

2015 Recipient: Ryutaro Kakinuma, MDNational Cancer Center Research Center for Cancer Prevention and Screening, Tokyo, Japan“Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study”Oral Session 24: CT Detected Nodules - Predicting Biological Outcome Tuesday, September 8; 10:45-12:15Rooms 401-404

Lectureship Awards Continued from page 3


WCLC 2015

Introducing the WCLC 2015 Meeting App!

Get 24-hour access to all conference related information

Access to full scientifi c program information including abstracts

Available for iPhone, iPad, Android and Mobile Website

Get it on Google Play or the App Store

JOIN THE CONVERSATION

WWW.IASLC.ORG

Young Investigator Scholarships and Developing Nation Awards

Ten young investigators and 10 researchers from developing nations received support to

attend the 16th WCLC with 2015 Young Investigator Scholarships and Developing Nation Awards.

Each of the award recipients sub-mitted an abstract that was chosen for presentation and worked on the research with a senior author who is an IASLC member. The scholarships and awards consist of complimentary

registration to the conference, funds to cover up to four nights’ accom-modation and travel expenses, and 1 year of membership in IASLC.

Young investigators are defi ned as re-searchers 35 years or younger, and de-

veloping nations are as defi ned by the IASLC Membership Guidelines, which corresponds to the World Bank list of countries.

The scholarships and awards are sponsored by Bristol-Myers Squibb.

2015 Young Investigator Scholarships

Lynnette Fernandez-CuestaInternational Agency for Research on Cancer, France “Genomic Characterization of Large-Cell Neuroendocrine Lung Tumors” Oral Session 06: Next Generation Se-quencing and Testing Implications Monday, September 7; 10:45-12:15Mile High Ballroom 1a-1f

Yoshihisa Kobayashi Kinki University Faculty of Medicine, Japan“EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Sensitivity to Afatinib or Neratinib but Not to Other EGFR-TKIs”Oral Session 03: New Kinase Targets Monday, September 7; 10:45-12:15 Mile High Ballroom 4a-4f

Ji Yun Lee Samsung Medical Center, South Korea“A Phase Ib/II Study of Afainib plus Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefi tinib or Erlotinib”Mini Oral 05: EGFR Mutant Lung Cancer 1Monday, September 7; 16:45-18:15Mile High Ballroom 2a-3b

Clara Peréz-Rambla Centro de Investigación Príncipe Felipe, Spain“Metabolomics by NMR Facilitates the Non-Invasive Diagnosis and Staging of NSCLC”Monday, September 7; 9:30-16:30Exhibit Hall B + C

Tomasz Powrózek Medical University of Lublin, Poland“Plasma Circulating MicroRNA-944 and

MicroRNA-3662 as Novel Histologic Type-Specifi c Lung Cancer Biomarkers”Poster Session 1Monday, September 7; 9:30-16:30Exhibit Hall B + C

Brandon Sheffi eldUniversity of British Columbia, Canada“Predictive Biomarker Testing for Programmed Cell Death 1 Inhibition in Non-Small Cell Lung Cancer”Oral Session 13: Immunotherapy Biomarkers Monday, September 7; 16:45-18:15 Four Seasons Ballroom F3 + F4

Kenichi SudaKinki University Faculty of Medicine, Japan“Qualitative and Quantitative Heterogeniety in Acquiring Resistance to EGFR Kinase Inhibitors in Lung Cancer” Oral Session 42: Drug Resistance Wednesday, September 9; 18:30-20:00 Mile High Ballroom 4a-4f

Dana TsuiUniversity of Cambridge, England“Circulating Tumor DNA for Noninvasive Monitoring of Non-Small Cell Lung Cancer Patients Receiving EGFR-Targeted Therapies” Mini Oral 26: Circulating Tumor MarkersWednesday, September 9; 16:45-18:15Rooms 205 + 207

Dawei Yang Zhongshan Hospital Fudan University, China“Clinical Application of Computer Assistant Diagnostic System in Probe-Based Confocal Laser Endomicroscopy (pCLE) for Pulmonary Diseases”Mini Oral 23: Lung Cancer Risk: Genetic Susceptibility and Airway Biology Tuesday, September 8; 16:45-18:15Rooms 401-404

Wenjing Zhang Chinese Academy of Sciences, China“Two Faces of YAP: Oncogenic in Lung Tumor Malignant Progression but Inhibitory in Phenotypic Transition”Oral Session 21: Biology - Moving Beyond the Oncogene to Onco-gene-Modifying GenesTuesday, September 8; 10:45-12:15Mile High Ballroom 4a-4f

2015 Developing Nations Award Recipients

Bernadette Reyna Asuncion De La Salle University, Philippines“PD-L1 Expression in Tumor Infi ltrating Immune Cells Determined by Digital Imaging Is Associated with Poor Survival in NSCLC Patients”Poster Session 2 Tuesday, September 8; 9:30-17:00Exhibit Hall B + C

María CastilloINCan Mexico “Different Mutation Profi les and Clinical Characteristics Among Hispanic Patients with NSCLC Could Explain the ‘Hispanic Paradox’”Oral Session 30: Community PracticeTuesday, September 8; 16:45-18:15Mile High Ballroom 2c-3c

Xiangkun HanChinese Academy of Sciences, China“Evidence and Mechanism for the Transdifferentiation of Lung Adeno-carcinoma to Squamous Cell Carcinoma”Oral Session 7: Lung Cancer PathogenesisMonday, September 7; 10:45-12:15Rooms 102 + 104 + 106

Tomi Kovacevi Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia“Acinar Subtype of Lung Adenocarcinoma Is Signifi cantly Related to EML4-ALK Translocation in Eastern European Patients”Poster Session 3 Wednesday, September 9; 9:30-17:00 Exhibit Hall B + C

Satya Narayan Acharya Tulsi Regional Cancer Treatment and Research Institute, India“A Prospective Randomized Phase III Study of Continuum Chemotherapy versus Chemo-Radiotherapy in ES-SCLC in Asian Indian”Oral Session 10: SCLCMonday, September 7; 10:45-12:15Rooms 605 + 607

Blessing Obiazi-OdiaseChildren Life Advancement Project, Nigeria“The Upshot of Passive Smoke (ETS) Exposure on Pneumonia Risk in

see Scholarships and Awards, page 15


Get the latest information on Lung Cancer Staging

Review information proposed by the IASLC about:

As published in the

(IARC; Lyon).

New Reference Cards freely available at the IASLC Booth (#3715) for the duration of the Conference.

Easy-to-read laminated cards

Spotlight on Advocacy: Prevent Cancer Foundation

The Prevent Cancer Foundation is internationally recognized as a leader in the fi ght against

cancer through prevention and ear-ly detection. Founded by Carolyn R. (“Bo”) Aldigé in 1985 in memory of her father, Edward P. Richardson, who died of cancer the previous year, the Foundation has invested nearly $140 million in research, education, outreach, and advocacy. The Founda-tion continues to serve as an import-ant partner with IASLC on many lung cancer prevention initiatives.

Since 2004, the Foundation has hosted a series of annual workshops on lung cancer quantitative imag-ing. The Prevent Cancer Foundation Workshop XII: “Quantitative Imag-ing: Screening and Tobacco-induced Disease Management,” held earlier this year, was co-sponsored by IASLC and Rush University. The workshop focused on two areas: accelerating partnerships in advancing new drugs to manage early lung cancer, and pol-icy implications of characterizing the

extent of tobacco injury to lung can-cer screening. Reports from previous workshops most recently have been published in the Journal of Thoracic Oncology.

“This workshop series has been very catalytic in the area of integrating quantitative CT imaging in ways that advance lung cancer outcomes both with lung cancer screening as well as with drug development,” says James Mulshine, MD, Vice Chair and Sci-entifi c Director at the Foundation, as well as Acting Dean of the Graduate College and Vice President and Asso-ciate Provost of Research at Rush Uni-versity, Chicago, Illinois.

IASLC and the Prevent Cancer Foundation have collaborated at

many levels through the years. At the WCLC 2000, the Foundation partnered with IASLC to establish a 2-year Fellowship program. With additional funding partners, this pro-gram continues to fl ourish, as this fellowship is often the fi rst funding source for new investigators. An early recipient of a Fellowship Award was Fred R. Hirsch, MD, PhD, now the CEO of IASLC. The Foundation also provided support for the 2015 IASLC Fellowship Awards.

“Early on in the Foundation, we felt it was critical to fund early-career re-searchers. This was a group that had a diffi cult time receiving funding, yet we were confi dent that their research would lead to important fi ndings in prevention and early detection,” says Carolyn Aldigé.

Ms. Aldigé, an IASLC member, serves on the Patient Advocates Com-mittee and the Prevention, Screening, and Early Detection Committee. She is vice chair of the Global Lung Can-cer Coalition and a member of the

advisory board of the International Early Lung Cancer Program. She is also extensively involved with other cancer-focused organizations, such as the Nation-al Coalition for Cancer Research, of which she served as presi-dent for 8 years, and C-Change as a member since its incep-tion. In addition, she serves on the Board of Directors or Board of Advi-sors for six National Cancer Institute-designated Cancer Centers and as a member of the board of four addi-tional nonprofi t cancer-related orga-nizations.

“We want to thank IASLC for con-tinuing to call attention to prevention and early detection. Thousands more people can live cancer-free by making healthy choices and getting recom-mended screenings,” she says.

Carolyn R. (“Bo”) Aldigé

Co

urte

sy o

f Pre

vent

Can

cer

Foun

dat

ion


New Mentorship Program Provides Opportunities to Early-Career Physicians in Developing Countries

The IASLC International Men-torship Program was established this year to provide profession-

al development and education for early-career physicians who are study-ing thoracic malignancies.

“The idea is to bring young lung cancer investigators, particularly from developing countries, to a mentored program at the WCLC and let them spend 1 week after the conference at the assigned mentor’s host institu-tion,” says Fred R. Hirsch, MD, PhD, IASLC CEO.

The program was well received, with more than 40 applicants from different disciplines and from all over the world. Candidates who apply to the Mentor-ship Program must submit an abstract for presentation at the WCLC and provide a personal statement on their goals and how the award will help them. The IASLC Fellowship Committee re-viewed applications and selected 13 ear-ly-career researchers from eight devel-oping countries.

The awardees will meet daily with

their assigned mentor during the con-ference to discuss relevant presenta-tions and scientifi c achievements. The week following the conference, six mentees will work with their mentors in various departments of the Univer-sity of Colorado, while the other sev-en will visit cancer institutions in New York, Ohio, Missouri, and Georgia. IASLC is grateful for the IASLC mem-bers who agreed to be mentors.

“We think this is a very important program for IASLC, and we strongly believe it will have an enormous impact for the awardees as well as for the en-vironment they are chosen from,” says Dr. Hirsch.

2015 MentorshipsRaharam Burrah, Regional Cancer Centre, India“The Role of Selective EBUS-TBNA Mediastinal Sampling in Early Lung Cancer”Mentor: Jessica Donnington, MD,Department of Cardiothoracic Surgery, and Director of Thoracic Surgery

Translational Laboratory, NYU Langone Medical Center, New York

Rafael Bitton, MD, Instituto do Cancer do Estado de Sao Paulo, University of Sao Paulo, Brazil“Validating ECOG Performance Status as a Prognostic Factor in Brazilian Patients with Pulmonary Adenocarcinoma” Mentor: Suresh Ramalingam, MD, Chief of Medical Oncology, Emory University School of Medicine, Atlanta, Georgia

Saul Campos Gomez, Centro Oncologico Estatal Issemym, Mexico“Experience with Docetaxel plus Nintedanib with Previously Treated NSCLC Patients: Compassionate Use Program Single Institution in Mexico”Mentor: Charles Rudin, MD, PhD, Chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York

Juliano Ce Coelho, Hospital de Clínicas de Porto Alegre, Brazil “Cofi lin-1 as a Biomarker for Non-Small Cell Lung Cancer and a Potential Predictor to Platinum-based Chemotherapy Resistance”Mentor: Ramaswamy Govindan, MD, Professor, Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri

Rania Gaber, Alexandria University, Egypt“Screening EGFR Mutations in NSCLC by Immunohistochemistry”Mentor: William Travis, MD, Director of Thoracic Pathology, Memorial Sloan Kettering Cancer Center, New York

Long Jiang, Sun Yat-sen University Cancer Center, China“Immunological Markers Predict the Prognosis of Patients with Squamous Non-Small Cell Lung Cancer”Mentor: John Mitchell, MD, Professor, Surgery-Cardiothoracic Surgery, Center for Surgical Innovation, University of Colorado Anschutz Medical Campus, Aurora

Maria Jose LaBanca, Hospital Italiano de Buenos Aires, Argentina“Correlation of ALK Status between FISH and Immunohistochemistry in Lung Cancer: a Multicenter Study of 738 Cases in Argentina”Mentor: Marileila Varella-Garcia, PhD, Professor, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora

Zoltan Lohinai, National Koranyi Institute of Pulmonology, Hungary

“Attempt to Validate Drug Repositioning for Metastatic Small Cell Lung cancer (SCLC) Therapy Identifi es Statins Associated with Survival Benefi t”Mentor: Paul Bunn, Jr., MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, Anschutz Medical Campus, Aurora

Daniela Morales-Espinosa, National Cancer Institute of Mexico“Analysis of Gene Expression in the Re-replication Pathway and Selective Blockade with Checkpoint Inhibitors as a Therapeutic Option in NSCLC”Mentor: David Carbone, MD, PhD, Director, James Thoracic Center, James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus

Ahmed Nagy, Ain Shams University-Cairo-Egypt, Egypt“Clinico-epidemiological features and Survival Outcome in Patients with NSCLC: Ain Shams Clinical Oncology Department 5-year Data”Mentors: Fred Hirsch, MD, PhD, Professor, Division of Medical Oncology, and Department of Pathology, and Theresa Boyle, MD, PhD, Assistant Professor, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora

Ren Shengxiang, Shanghai Pulmonary Hospital, Tongji University, China“EML4-ALK Fusion Detected by qRT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced NSCLC” Mentor: D. Ross Camidge, MD, PhD, Professor, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora

Roy Soumyajit, All India Institute of Medical Sciences, India“Effi cacy of 18-FDG PET SCAN as Predictor of RR in NSCLC”Mentor: Kavita Garg, MD, Professor, Radiology-Diagnostics, Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora

Phannin Tiraswasdichai, Ramathibodi Hospital, Faculty of Medicince, Mahidol University, Thailand“Prognostic Factors in LCC /NET”Mentor: Alex Adjai, MD, PhD, Professor and Chair, Department of Medicine, Senior Vice President of Clinical Research, The Katherine Anne Gioia Chair in Cancer Medicine, Roswell Park Cancer Institute, Buffalo, New York

Included in your Conference registration

Use your registration ID number printed on your badge to get access

No more missing out on presentations

Watch all presentations fromWCLC 2015 within 24 hours!

INCLUDES

Abstracts Presentation slides Audio/video recording of presentations Electronic version of most posters

GET ACCESS TO THE VIRTUAL MEETING VIA THE CONFERENCE AND IASLC WEBSITE

WWW.IASLC.ORG


of several awards for these activities, including The Outstanding Pole Rec-ognition, Man of the Year, Polska, The Times, and Health Promotion Foun-dation Golden Award. He is a mem-ber of the IASLC Smoking Cessation and Tobacco Control Committees and advises other countries on this topic. Professor Jassem also under-took other nationwide public health initiatives, such as the coordination of Cancer Control Strategy for Poland 2015-2024.

“Dr. Jassem is a leader in thoracic oncology in central Europe and inter-nationally. He is a good collaborator and has made signifi cant contributions to reduce the burden of smoking haz-ards around the world,” Dr. Hirsch says.

Mary J. Matthews Pathology/Translational Research Award: Dr. Ming Tsao

Ming Tsao, MD, FRCPC, is Consul-tant Thoracic Pathologist, Senior Sci-entist, and M. Qasim Choksi Chair in Lung Cancer Translational Research at the Princess Margaret Cancer Cen-tre. Additionally, he is a Professor of Laboratory Medicine and Pathobiolo-gy and Medical Biophysics at the Uni-versity of Toronto.

Dr. Tsao has been Director of the Canadian Institutes of Health Research training program in molecular pathol-ogy of cancer since 2002; Co-Director of the Advanced Optical Micro-imag-ing Facility, Ontario Cancer Institute; Director of the Advanced Molecular Profi ling and Drug Discover Program; and Biomarker Laboratory member of the Canadian Cancer Society Advisory Committee on Research. His current lung cancer research activities include

biomarkers in targeted cancer thera-py, molecular prognostic and predic-tive markers and pathobiology of lung cancer, tumor cell stromal interaction, Ras oncogene, and application of novel optical/Raman technologies for tissue/cellular and in vivo imaging.

“Dr. Tsao is a leader in lung cancer pathology and biology and has trained many international scientists,” says Dr. Hirsch. “He is a pioneer in trans-lational research for thoracic malig-nancies.”

Dr. Tsao has been a member of the IASLC Pathology Committee since 2006, serving as Chair from 2011 to 2013. In 2011, he became a mem-ber of the International Staging and Prognostic Factor Committee. He is an organizing member and speaker of the webinar, “Introducing the New IASLC/ATS/ERS Lung Adenocar-cinoma Classifi cation”; Co-Editor of IASLC ATLAS of ALK Testing in Lung Cancer; and chapter coauthor of Thoracic Oncology: The IASLC Multi-disciplinary Approach. He is a past As-sociate Editor of the Journal of Tho-racic Oncology; and a member of the International Program Committee for this WCLC as well as the past two WCLCs.

Dr. Tsao earned his medical degree at the University of British Columbia and his FRCPC at Royal College of Physicians and Surgeons of Canada. He served his residency in anatom-ic pathology at McGill University in Montreal, followed by a fellowship in experimental pathology at the Univer-sity of North Carolina. He has served on the Editorial Board of the Journal of Clinical Oncology and as a member of the International Advisory Board of the Canadian Journal of Pathology. He is also a member of the Canadian Cancer Society Advisory Committee on Re-search.

In 2010, the Canadian Cancer Soci-ety honored Dr. Tsao with the 2011 O. Harold Warwick Award in recognition

of his extraordinary contributions and work toward advancing the science of lung cancer.

The Paul A. Bunn, Jr. Scientifi c Award is given to an IASLC scientist for life-time achieve-ment in scientifi c contributions to thoracic cancer research. Robert Ginsberg, MD, a thoracic surgeon from Toronto, Canada, earned the fi rst award in 1994 for his contributions to the surgi-cal treatment of early-stage lung can-cer. IASLC named the award after Dr. Bunn in 2013, when he stepped down after serving as executive director/CEO of IASLC for 12 years. Dr. Bunn also served as President of IASLC (2002-2003), as well as of other organizations, including the American Association of Cancer Institutes and the American So-ciety of Clinical Oncology.

The IASLC Merit Award is given to a member who has made an extraordi-nary contribution to the development of the Association. The Merit Award is the fi rst IASLC Distinguished Award established, and the fi rst recipient was Clifton Mountain, MD, in 1991.

The Joseph W. Cullen Prevention/Early Detection Award is given to an IASLC scientist for lifetime scientifi c achievements in research on the pre-vention of thoracic malignancies. Dr. Cullen served as the Deputy Director of the NCI Division of Cancer Preven-

tion and Control. He created the Smoking Tobac-co and Cancer Program (STCP) at the NCI in 1982. The winner of the fi rst award in 1994 was Jes-se Steinfeld, MD, the US Surgeon General when the sen-tinel 1964 Surgeon General’s report on tobacco was fi rst issued.

The Mary J. Matthews Pathology/Translational Research Award is giv-en to an IASLC scientist for life-time scientifi c achievements in pathology/trans-lational research of thoracic ma-lignancies. Dr. Matthews was a Senior Investi-gator and Pathologist at the National Cancer Institute (NCI) Medical Oncol-ogy Branch and a pioneer in the foun-dation of the histological subtypes of lung cancer and the relationship be-tween those subtypes and the clinical course of lung cancer. She was the fi rst to recognize that small cell lung cancer was disseminated at the time of diagnosis, leading to distinctions between small cell lung cancer and non-small cell lung cancer.

Paul A. Bunn, Jr., MD

Joseph W. Cullen, MD

Mary J. Matthews, MD

The AwardsAwards Continued from page 2

Plenary Session to Highlight What’s New in Lung Cancer Screening and Prevention

Early detection of lung cancer results in dramatically higher survival rates. Most lung can-

cer, however, is caught late, when the disease is more diffi cult to treat. At Monday’s Plenary Session, three experts will present the newest in-formation about prevention and ear-ly detection. Carolyn Dresler, MD, MPA, Associate Director for Medical and Health Sciences in the Offi ce of Science at the FDA Center for Tobac-co Products Offi ce, and Harvey Pass, MD, Director of the Thoracic Sur-gery Division at New York University Medical Center, serve as co-chairs of the session.

Christine Berg, MD, former lead

investigator of the National Lung Screening Trial (NLST), will address what the NLST results have contrib-uted to the knowledge base over the last 2 years. She also will discuss the rationales for the Medicare coverage policy and US Preventive Services Task Force recommendations for lung cancer screening, as well as alternative approaches to setting risk thresholds for screening that might be more ef-fective and effi cient.

“Lung cancer screening is a pro-cess,” Dr. Berg says. “Going forward, multidisciplinary programs will need to monitor outcomes to maximize benefi ts and minimize harms.”

One of the best ways to avoid lung

cancer is not to smoke. David Chris-tiani, MD, PhD, Elkan Blout Pro-fessor of Environmental Genetics, Environmental Health, Harvard T.H. Chan School of Public Health, will talk about the global epidemiology of smoking. He will focus on the re-lationship that exists between onset and prevalence of smoking and the incidence and mortality of lung can-cer, and strategies that could prevent lung cancer deaths in countries with still-developing smoking epidemics.

Tobacco cessation after a can-cer diagnosis is also important, and Graham Warren, MD, PhD, Direc-tor, Hollings Cancer Center Tobac-co Cessation Program at the Medical

University of South Carolina, will discuss this topic. In particular, he will focus on the known biologic effects of smoking on cancer cell biology and the impact of persistent smoking on outcomes in patients undergoing treatment for cancer. The 2014 Re-port of the US Surgeon General was the fi rst such report to describe the impact of smoking after a cancer di-agnosis, Dr. Dresler says. “Graham continues to build on this science.”

f h l ll

Plenary Session

Monday, September 7; 8:15-9:45

Plenary Hall (Bellco Theater)


New IASLC President-Elect and Board Members Have Vision for the Future

The newly elected President-Elect and seven IASLC Board of Di-rectors members, introduced be-

low, are eager to begin their 4-year term and look forward to further enhancing IASLC’s position as the global leader in lung cancer. In describing their in-dividual priorities and goals for the So-ciety, the new Board members touched on several common themes: continuing tobacco control efforts as a priority, increasing membership and diversity, targeting young researchers, expanding educational activities, and developing global initiatives to facilitate research. (Learn about the goals of the new IASLC

President, David Carbone, MD, PhD, in the Wednesday issue.)

Continuing Tobacco Control as a Priority

Dr. Scagliotti notes that the fi ght against tobacco should remain among IASLC’s main priorities. “Any reason-able and sound approach should be pursued to improve control of the to-bacco epidemic, with special programs dedicated to teenagers and approach-ing the problem in a more sophisticat-ed and multidisciplinary way,” he says.

Dr. Pirker agrees, adding that he hopes to establish smoking cessation/

early detection units in cancer centers in Central and Eastern Europe to help decrease the high lung cancer burden in this region. “I will seek to enhance co-operation between IASLC, government and nongovernmental organizations , and the media to emphasize the positive effects of tobacco control and smoking cessation for global health,” he says.

Increasing Membership and Diversity

Dr. Scagliotti wants IASLC to be-come an umbrella organization for all health care professionals involved in thoracic malignancies. Other board

members note the need to diversi-fy membership by expanding the in-vitation of membership to specifi c groups of health care professionals. For example, Dr. Reck says he would like to include other members of the interdisciplinary lung cancer team, such specialized nurses, psychologists, members of palliative care teams, and representatives from patient advocacy groups. “These professionals would contribute signifi cantly to the expertise of IASLC,” he says. Dr. Wakelee adds that IASLC should extend outreach to

Meet the New IASLC Board MembersEarlier this year, IASLC members elected a President-Elect and seven Board of Directors members. To learn more about the goals and priorities of these new Board members, see article above.

Giorgio V. Scagliotti, MD, PhD, President-ElectDr. Scagliotti is Chief of the Med-ical Oncology Division at the S. Luigi Hospital, Or-bassano (Torino), and Head of the Department of Oncology at University of Torino. He was a member of the IASLC Board of Direc-tors in 2003-2007 and he is an Associate Editor for Journal of Thoracic Oncology and International Editor for Clinical Lung Cancer. He is a co-editor of the textbook, The IASLC Textbook of Multidisciplinary Approach to Thoracic Oncology and is the International Editor of the fourth edi-tion of Lung Cancer: Principles and Prac-tice. In addition to IASLC, Dr. Scagliotti is a member of the Italian Association of Medical Oncology, the European Respi-ratory Society, and the American Society of Clinical Oncology (ASCO).

Michael Boyer, MBBS, PhD, BOD AsiaDr. Boyer is a medical oncol-ogist at Chris O’Brien Life-house Cancer Centre in Sydney, Australia, and is a Clinical Profes-sor at the University of Sydney. He has been a member of the IASLC Fellowship Committee and Bylaws Committee, also serving as chair of the latter committee. He was the conference Co-President for the 15th WCLC held in Sydney in 2013. He served as Chair of the Scientifi c Ad-visory Committee of the Australasian Lung Cancer Trials Group.

David Harpole, MD, BOD North AmericaDr. Harpole is a Professor of Surgery in the Division of Car-diothoracic Sur-gery at Duke Uni-versity Medical Center, Durham, North Carolina, where he serves as Vice Chair of Research in the Department of Surgery and directs the Lung Cancer Research Laboratory and Biorepository. He has been extensively involved with clinical trials, serving as the Chair of the Cancer and Leukemia Group B (CALGB) Thoracic Surgery Subcommittee, as the Vice Chair of the American College of Surgeons Oncology Group, and as Co-chair of the Thoracic Tumor Committee of the National Cancer Database.

Norihiko Ikeda, MD, PhD, BOD JapanNorihiko Ikeda is the Vice President and Chair of the Department of Thoracic Surgery, Tokyo Medical University, Tokyo, Japan. He is a member of the Board of Directors and Head of the International Committee of the Japan Lung Cancer Society, which is the offi cial liaison society of the IASLC in Japan. He has translated every IASLC newsletter and item of communications into Japanese to maximally facilitate the dissemination of all IASLC-related infor-mation among other lung cancer physi-cians in his country.

Robert Pirker, MD, BOD EuropeRobert Pirker is currently Professor of

Medicine and Program Director for Lung Cancer at the Depart-ment of Medi-cine I, Medical University of Vi-enna, Austria. He was a member of the IASLC Education Committee, also serving as chair, and is the Conference President of the 2016 WCLC in Vienna. He is also the Chair of the Steering Committee of the Central European Initiative against Lung Can-cer and a Board member of the Central European Lung Cancer Conferences.

Martin Reck, MD, PhD, BOD EuropeDr. Reck is Head of the Depart-ment of Tho-racic Oncology and Head of the Clinical Trial De-partment in the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf, Germany. In addition to IASLC, he is a member of the European Society for Medical Oncology (ESMO), ASCO, the German Working Group for Lung Cancer, the German Cancer So-ciety, and the German Society of Pul-monology.

Miyako Satouchi, MD, PhD, BOD AsiaDr. Satouchi is the head of Tho-racic Oncology at the Hyogo Cancer Center in Akashi, Japan. She is an active member of the Japan Clinical Oncology Group and the West Japan Oncology Group. She has also served as a Councilor and a member of the

Guideline Committee of the Japanese Society of Medical Oncology (JSMO), and as a Councilor and member of the Biomarker and International Commit-tees of the Japan Lung Cancer Society. In addition, she is a member of ASCO and ESMO.

Heather Wakelee, MD, BOD North AmericaDr. Wakelee is an Associate Profes-sor of Medicine in the Division of Oncology at Stanford Univer-sity, Stanford, California, and is the faculty director of the Stanford Cancer Clinical Trials Offi ce. She has been an active IASLC member for more than a decade, serving as a member of the Communications Committee (chair, 2011-2013), as a US representative to the Council of Regents (2010 to pres-ent), and on WCLC–related committees (2007 to present). She also co-chaired the 2013 Best of WCLC in San Francisco.

These incoming Board members will join the following members, whose terms continue until 2017: Francoise Mornex, MD, PhD, University Claude Bernard, Lyon, France; Keith Kerr, BSc, MB, ChB, University of Aberdeen, Ab-erdeen, Scotland; William Travis, MD, Memorial Sloan Kettering Cancer Cen-ter, New York, New York; Solange Pe-ters, Md, PhD, PD-MER, University of Lausanne, Lausanne, Switzerland; Laurie Gaspar, MD, MBA, University of Col-orado, Denver, Colorado; Pasi Janne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts; Yuichiro Ohe, MD, National Cancer Center Hospital East, Chiba, Japan; and Yi-Long Wu, MD, Guangdon Lung Cancer Institute, Guangzhou, PR China.

see IASLC Board Members, page 15


History and Growth of IASLC

The International Association for the Study of Lung Cancer (IASLC) was established in 1974,

emerging from the First Internation-al Workshop for the Therapy of Lung Cancer, which was offered by the US National Cancer Institute. Approxi-mately 115 individuals from 15 coun-tries met at this workshop to discuss the benefi t of a multidisciplinary approach to the treatment of lung cancer. One attendee, David T. Carr, MD, of the Mayo Clinic, Rochester, Minnesota, in-troduced the idea of forming an inter-national organization to continue the exchange of ideas and research on this topic. Along with colleagues Oleg S. Selawry, MD, Lawrence Broder, MD, and George Higgins, MD, Dr. Carr led an organizational committee to develop the association that became IASLC.

Early LeadershipBy the middle of 1974, approximately

250 individuals had joined the associa-tion, and the fi rst organizational meet-ing of IASLC was held in conjunction with the XIth International Cancer Congress, sponsored by the Union for International Cancer Control (UICC) in Florence, Italy. The inaugural slate of offi cers and Board of Directors were selected at this meeting. The Founding Offi cers were Oleg Selawry, President; David Carr, Vice President; Clifton Mountain, President-elect; Lawrence Broder, Secretary; and George Hig-gins, Treasurer. The Board of Directors included international representation, with Pierre Alberto, Johannes Clem-mensen, Shichiro Ishikawa, Lucien Is-rael, F. G. Pearson, and Roy Ritts. To date, 18 physicians have led the organi-zation, representing countries in North

America, Europe, and Asia (see sidebar). In 1994, growth in membership led

the Board of Directors to create the position of Executive Director (CEO), and Heine H. Hansen, MD, established the fi rst IASLC offi ce in Copenhagen, Denmark, and served as CEO from 1994-2003. The IASLC offi ce moved to Denver, Colorado, when Paul A. Bunn, Jr., MD, followed Dr. Hansen as CEO in 2003. Dr. Bunn stepped down in 2013, and Fred R. Hirsch, MD, PhD, became CEO in 2013.

Growing the IASLC Global TeamMembership in IASLC doubled in

its fi rst 5 years—from 250 in 1974 to 500 in 1979—and it has grown steadi-ly since then. Since 2005, membership has tripled, and just since last year, 1,100 new members have joined (Fig-ure). The growth in membership is the result of the efforts of the IASLC Membership Committee, which is charged with developing strategies to increase membership and retain mem-bers. One initiative was to enhance visibility of IASLC through its Mem-bership Exhibit Booth, and the booth was displayed at the American Thorac-ic Society and the European Society of Thoracic Surgeons meetings in 2015.

“Though these exhibits, we were able to engage many new members and po-tential members in the fi elds of pulmo-nary medicine, interventional pulmon-ology, and thoracic surgery from around the world,” says Kristin Richeimer, IASLC Director of Membership.

Another strategy was to offer dis-counted rates with partner societies that have missions similar to IASLC’s mission. Through this discount pro-gram, IASLC offers a one-time, in-troductory discounted membership to new members. These memberships maintain all member benefi ts, except all 1-year offers are non-voting mem-berships. The nine partner societies in-clude the following.• Brazilian Society of Pathologists• Brazilian Society of Thoracic Surgery• British Thoracic Oncology Group • European Society of

Thoracic Surgeons • Indian Society for Study of

Lung Cancer • International Thoracic Oncology

Nurses Forum/National Lung Cancer Forum for Nurses

• Japan Lung Cancer Society • Korean Association for the Study of

Lung Cancer • Pulmonary Pathology Society

“We will continue to actively interact with current and potential partner so-cieties as the IASLC has considerable expertise that we would like to share

with health care professionals,” says Suresh Senan, MD, PhD, Chair of the IASLC Membership Committee. Dr. Senan adds that attendees are encour-aged to contact IASLC by mail or at the IASLC Booth to discuss ideas for potential collaborations.

IASLC recently launched member feedback surveys as a way to better meet the needs of its diverse members. Nearly 20% of members responded to the 2014 survey to provide feedback

on IASLC membership and programs. Members noted that the top three rea-sons they joined IASLC were (in order) the Journal of Thoracic Oncology, net-working opportunities, and the sub-stantial WCLC member discount.

Learn more about IASLC member-ship at the IASLC Booth in the Exhibit Hall (Booth #3715). Bring your 2015 membership card to the IASLC Booth to claim your member pin and tote bag.

The IASLC Multidisciplinary Approach to

Thoracic Oncology

Special Price

US $50

for WCLC 2015 Attendees

An invaluable educational tool for any health professional who interacts with individuals at risk for lung cancer or other thoracic cancers.

Paul A. Bunn, Jr., MD, and Fred R. Hirsch, MD, PhD

“

”

Visit the IASLC Booth (#3715) and Order your Copy

Expanding the basics of thoracic oncology and a primer on new concepts.

Comprehensive resource for lung cancer prevention, early detection, staging, diagnosis, and care.

IASLC Presidents

1974-1976: Oleg Selawry, USA

1976-1977: David Carr, USA

1977-1978: Clifton Mountain, USA

1978-1980: George Higgins, USA

1980-1982: Pierre Alberto, Switzerland

1982-1985: Shiohiro Ishikawa, Japan

1985-1988: Ronald Vincent, USA

1988-1991: Heine Hansen, Denmark

1991-1994: Yoshihiro Hayata, Japan

1994-1997: Paul A. Bunn, Jr., USA

1997-2000: Giovanni Motta, Italy

2000-2003: Harumbi Kato, Japan

2003-2005: Frances Shepherd, Canada

2005-2007: Desmond Carney, Ireland

2007-2009: Nagahiro Saijo, Japan

2009-2011: David Gandara, USA

2011-2013: Peter Goldstraw, UK

2013-2015: Tony Mok, Hong Kong

Figure. Growth in IASLC membership since 2005.

1,500

2,050 2,0002,175 2,125

2,775 2,925

3,700 3,800

3,400

4,500

2,000

1,000

0

4,000

3,000

5,000

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Year

No.

of M

embe

rs


Schedule at a Glance: Monday07:00 - 08:00

Meet the Expert Sessions (ticketed sessions)

MTE 01: Endpoints in Clinical Trials in Advanced NSCLC Tony Mok, Hong Kong, and Gideon Blumenthal, USARoom 103

MTE 02: Patients, Investigators and Pharmaceuticals Working Together to Accelerate Research and Access: The Lung Cancer Master Protocol (Lung-MAP) Clinical Trial Vassiliki Papadimitrakopoulou, USA, and Kim Norris, USARoom 105

MTE 03: Squamous Cell Lung Cancer Howard West, USARoom 107

MTE 04: Molecular Testing in Community Settings John Longshore, USARoom 109

MTE 05: Role of the Interventional Pulmonologist and Medical PleuroscopyPyng Lee, SingaporeRoom 111

MTE 06: Curative Radiotherapy for Local or Locoregional Disease Yasuhi Nagata, Japan, and Joseph Salama, USARooms 102 + 104 + 106

MTE 07: Pharmacologic and Non-Pharmacologic Management of Dyspnea Alex Molasiotis, Hong KongRooms 108 + 110 + 112

MTE 08: Tobacco Control: What Do the Experts Do? Emily Stone, Australia, and Ellen Gritz, USARooms 702 + 704 + 706

MTE 09: Treatment of Advanced SCLC including Second Line Taofeek Owonikoko, USA, and Caicun Zhou, ChinaRooms 708 + 710 + 712

MTE 10: Subsolid Nodules: What the Clinicians Need to Know / Clinical Workup of CT Detected Nodules Kavita Garg, USA, and Reginald Munden, USARoom 703

MTE 11: Mediastinal Tumors Including Thymic Tumors, Lymphoma, Germ-Cell Tumors: Biology, Diagnosis and Treatment Lawrence Einhorn, USA; Gregory Riely, USA; and Enrico Ruffi ni, ItalyRooms 201 + 203

08:15 - 09:45

Plenary: Lung Cancer Prevention and Screening

Plenary Hall (Bellco Theatre)

09:45 - 10:45

Networking Break and Poster Session 1

Exhibit Hall (Hall B + C) Refreshments will be provided

10:45 - 12:15

Oral Sessions

Oral Session 01: Chemotherapy Developments for Lung CancerRooms 401-404

Oral Session 02: PD1 Axis Immunotherapy 2Four Seasons Ballroom F1 + F2

Oral Session 03: New Kinase TargetsMile High Ballroom 4a-4f

Oral Session 04: Adjuvant Therapy for Early Stage Lung CancerRooms 205 + 207

Oral Session 05: SurgeryRooms 201 + 203

Oral Session 06: Next Generation Sequencing and Testing ImplicationsMile High Ballroom 1a-1f

Oral Session 07: Lung Cancer PathogenesisRooms 102 + 104 + 106

Oral Session 08: Smoking Cessation, Tobacco Control and Lung CancerRooms 601 + 603

Oral Session 09: CT Screening - New Data and Risk AssessmentMile High Ballroom 2a-3b

Oral Session 10: SCLCRooms 605 + 607

Oral Session 11: Clinical Trials 1Rooms 702 + 704 + 706

Oral Session 12: Quality of Life and TrialsRoom 708 + 710 + 712

10:45 - 12:15

Mini Oral Sessions

Mini Oral 01: PathologyMile High Ballroom 2c-3c,

Mini Oral 02: ImmunotherapyFour Seasons Ballroom F3 + F4

14:15 - 15:45

Mini Symposia

MS 01: How to Treat Multiple GGOsRooms 102 + 104 + 106

MS 02: Are Non-Tissue Biomarkers Ready for the Clinic?Rooms 401-404

MS 03: Is Tumor Angiogenesis Still a Viable Target in Advanced NSCLC?Rooms 605 + 607

MS 04: Harnessing the Full Potential of the Immune SystemFour Seasons Ballroom F3 + F4

MS 05: Tumor HeterogeneityMile High Ballroom 1a-1f

MS 06: Regulation of Tobacco ProductsRooms 201 + 203

MS 07: SCLC Biology & ModelsMile High Ballroom 4a-4f

MS 08: BAP1 Cancer Syndrome and MesotheliomaRooms 702 + 704 + 706

MS 09: Worldwide Perspective/Review of Limitations, Resources, Programs and Accomplishments of Supportive Care and Palliative Care Multidisciplinary Teams, by ContinentRooms 108 + 110 + 112

MS 10: Management of Screening Detected Lung CancerMile High Ballroom 3a-3c

14:15 - 15:45

Education Sessions

ED 01: Update in Radiation OncologyRooms 205 + 207

ED 02: Molecular Testing around the World (Genomics in Clinic (Timelines/Bioinformatics), Testing Platforms & Algorithms (NGS, Targeted Panels, FISH, IHC), Cost Considerations, Strategies for Identifying Rare Genomic Subsets in Clinical Trials)Room

ED 03: Global Lung Cancer Coalition – Data-Driven Lung Cancer AdvocacyRoom 703

ED 04: How to Set up a Multidisciplinary Lung Cancer Program within a Community Care Environment and Provide Everyone with the Best Care for Lung CancerMile High Ballroom 2a-2c

ED 05: Case Presentations (3 Lung Cancer and 1 Mesothelioma) Discussed in Round Table FormatRooms 708 + 710 + 712

Pro Con

PC 01: Surgery vs. SBRT in Operable NSCLC /Pro vs Con: SBRT for Non-Biopsied Lung NodulesRooms 601 + 603

15:45 - 16:45

Networking Break and Poster Session 1

Exhibit Hall (Hall B + C) Refreshments will be provided

16:45 - 18:15

Oral Sessions

Oral Session 13: Immunotherapy BiomarkersFour Seasons Ballroom F3 + F4

Oral Session 14: Biology 2Rooms 702 + 704 + 706

Oral Session 15: Outcome Management in Lung Cancer PatientsRooms 102 104 106

Mini Oral Sessions

Mini Oral 03: PD1 Axis Inhibition and EGFRFour Seasons Ballroom F1 + F2

Mini Oral 04: Clinical Care of Lung CancerMile High Ballroom 2c-3c

Mini Oral 05: EGFR Mutant Lung Cancer 1Mile High Ballroom 2a-3b

Mini Oral 06: Quality/Prognosis/SurvivalRooms 605 + 607

Mini Oral 07: ChemoRT and Translational ScienceRooms 201 + 203

Mini Oral 08: Prognostic/Predictive BiomarkersMile High Ballroom 4a-4f

Mini Oral 09: Drug ResistanceRooms 205 + 207

Mini Oral 10: ALK and EGFRMile High Ballroom 1a-1f

Mini Oral 11: Tobacco Control and PreventionRooms 601 + 603

Mini Oral 12: Biomarkers and Lung Nodule ManagementRooms 401-404


To learn more about OPDIVO, stop by Booth 1617 and visit www.opdivo.com/hcp

OPDIVO® and the related logo are trademarks of Bristol-Myers Squibb Company. ©2015 Bristol-Myers Squibb Company. All rights reserved. Printed in USA. 1506US15BR00841-10-01 07/15 For U.S. Healthcare Professionals Only

Session Focuses on Regulation of Tobacco Products

Tobacco is used by about 1 billion people worldwide; nearly 80% of them living in developing and

underdeveloped countries. Up to half of the people who use tobacco will ul-timately die from its use, accounting for about 6 million deaths each year. By 2030, the death toll directly linked to tobacco use is projected to rise to 10 million people annually. Given these statistics, it is no surprise that tobacco is one of the most intensely debated and heavily regulated substances in the world.

Monday afternoon, the latest infor-mation on the regulation of tobacco products will be presented in a mini symposium chaired by Nise Yama-guchi, MD, Executive Director, In-stitute of Advances in Medicine, São Paulo, Brazil, and Edgardo Santos, MD, FACP, Medical Director, Can-cer Research, Lynn Cancer Institute, Boca Raton, Florida. The symposium focuses on four key topics: the global effect of smoking, the World Health Organization (WHO) Framework Convention on Tobacco Control, the regulation of tobacco products in the United States, and the role of litiga-tion in controlling tobacco.

The global effects of smoking, of quitting, and of taxing tobacco will be discussed by Luk Joossens, Advo-cacy Offi cer, Association of European Cancer Leagues, Tobacco Control Expert, Belgian Foundation Against Cancer, and International Expert on Illicit Tobacco Trade. The American Cancer Society considers Mr. Joos-sens, author of more than 250 articles,

reports, and presentations on various aspects of tobacco control, to be “one of the world’s foremost tobacco con-trol advocates for almost 30 years.”

Geoffrey Fong, PhD, Professor of Psychology and of Public Health and Health Systems, University of Wa-terloo, Ontario, Canada, will discuss the WHO Framework Convention on Tobacco Control, the fi rst-ever global health treaty negotiated under the auspices of WHO. Dr. Fong is Founder and Chief Principle Inves-tigator of the International Tobacco Control Evaluation project, whose overall objective is to conduct rigor-ous evaluation of the psychological and behavioral effects of tobacco con-trol policies of the Framework Con-vention.

The regulation of tobacco products by the US Food and Drug Adminis-tration (FDA) will be discussed by Mitch Zeller, JD, Director, Center for Tobacco Products, FDA, Bethesda, Maryland. The Center for Tobacco Products has the authority to regulate

the manufacturing, marketing, and distribution of all tobacco products (cigarettes, cigarette tobacco, roll-your-own, and smokeless) intended for human consumption. It also has the authority to assert jurisdiction over other products that meet the defi -nition of a tobacco product, including e-cigarettes, cigars, and hookah.

The role of litigation in controlling tobacco use will be discussed by Rich-ard Daynard, JD, PhD, Professor of Law, Northeastern University, Bos-ton, Massachusetts. Professor Day-nard is at the forefront of an interna-tional movement to establish the legal responsibility of the tobacco industry for tobacco-induced death, disease, and disability.

the manufacturing marketing and

MS 06: Regulation of Tobacco Products

Monday, September 714:15-15:45

Rooms 201 + 203


Enjoy the Mile High City

Denver has many options for you, no matter how you enjoy spending your free time. To get

the most out of this fascinating city, download the Offi cial Visitor app de-veloped by the Denver Tourism and Visitors Bureau. The app is available on the iTunes store (for iPhone and iPad) or from Google Play or the Android Marketplace.

DiningDenver features 2,000 restaurants,

300 of which are within walking dis-tance of the Colorado Convention Center. Area specialties include South-western dishes, buffalo, Colorado beef and lamb, and fresh produce. Eat Drink Denver (http://eatdrinkdenver.com/) offers guides on must-try Denver restaurants, great food trucks, and free tours of food and drink hot spots.

The lower downtown area, referred to as Denver’s LoDo district (http://www.lodo.org/), is the city’s oldest neighborhood and features 28 square

blocks of restaurants, sports bars, and brewpubs. Live music is offered in many bars and restaurants.

Museums

Denver Art Museumhttp://denverartmuseum.org/

The Denver Art Museum, within walking distance of the Convention Center, features international works and houses one of the world’s most comprehensive collections of Native American art works.

Denver Museum of Nature & Science http://www.dmns.org/

Visit The Power of Poison exhibi-tion, as well as a variety of permanent

exhibitions, such as Konovalenko: Gem Carvings of Russian Folk Life, North American Indian Cultures, Egyptian Mummies, Space Odyssey, and Wildlife Exhibits. The museum also features an IMAX movie theater and a planetarium.

Morrison National History Museumhttp://www.mnhm.org/246/Morrison-Natural-History-Museum

A paleontology museum that provides visitors with expert guides and hands-on exhibits. Located 25 minutes west of downtown Denver, in Morrison.

Nature

Denver Botanic Gardens http://www.botanicgardens.org/

The Gardens offer spectacular plant-ings, a conservatory, rotating exhibits, and themed gardens.

Denver Zoohttp://www.denverzoo.org/events

Exhibits include the Toyota Elephant Passage, Benson Predator Ridge, Gi-raffe Encounter, Primate Panorama, Tropical Discovery, North Shores, Birds, Bear Mountain, Pachyderms, and Felines. Guided tours and animal adventures are available.

Downtown Aquariumhttp://www.aquariumrestaurants.com/downtownaquariumdenver/

More than 1 million gallons of un-derwater exhibits (both fresh water and ocean ecosystems) and over 500 species of sea life. The Aquarium features an interactive touch tank, coral lagoon, and restaurant. The restaurant is sur-

rounded by a 50,000-gallon tank of brightly colored tropical fi sh from the Caribbean, Hawaii, South Pacifi c, and Indian Ocean.

Shopping

16th Street Mallhttp://16thstreetmalldenver.com/

A pedestrian promenade lined with 50,000 fl owers that runs for more than a mile through the heart of downtown Denver and just a few blocks from the Convention Center. Shops include the decades-old bookshop, The Tattered Cover.

Cherry Creek Shopping Centerhttp://www.shopcherrycreek.com/

An ultra upscale mall with nearly 500 department stores, art galleries, shops, and boutiques. Located 3 miles from downtown Denver.

The Source www.thesourcedenver.com/

A marketplace established in a 26,000-square-foot, 19th-century ware-house. The Source offers local brewers, bakers, butchers, specialty grocers, and craftsmen, all under one roof.

Information courtesy of www.denver.org.

10 Denver Facts1. Denver truly is 1 mile high; the distance is measured from a step on the

State Capitol Building.

2. Between 1858 and 1888, the population of the Denver metro area grew from zero to 200,000; the growth was due to a gold rush.

3. The sun shines 300 days a year in Denver, offering more hours of sun than San Diego or Miami Beach.

4. Denver offers the 10th largest downtown in America—and it’s one of the most walkable downtowns in the country.

5. There are 200 named mountain peaks visible from Denver; 32 of them are 13,000 feet high or more.

6. Denver has the country’s largest city park system, offering more than 200 parks within the city and 20,000 acres of parks in the nearby mountains.

7. Denver is one of only a few cities in the United States to have seven professional sports teams, along with horse racing and a professional rodeo.

8. Denver is emerging as a model of a sustainable city, with strong programs for solar power, tree planting, and environmental cleanup.

9. Denver brews more beer than any other city in the United States, with 200 different beers brewed in town daily.

10. Denver is farm-fresh, with restaurants and gourmet food trucks offering fresh, local ingredients.

Tips for Dealing with Denver’s High AltitudeThe air is thinner a mile above sea level, and some simple steps will help you adjust.

• Drink plenty of water

• Eat foods high in potassium

• Be cautious with alcohol

• Pare down your exercise program

Pho

to C

red

it: V

ISIT

DE

NV

ER

Pho

to C

red

it: V

ISIT

DE

NV

ER

Pho

to C

red

it: S

teve

Mo

hlen

kam

p /

V

ISIT

DE

NV

ER

Pho

to C

red

it: V

ISIT

DE

NV

ER

Pho

to C

red

it: J

eff W

ells

/

VIS

IT D

EN

VE

R

Pho

to C

red

it: V

ISIT

DE

NV

ER

Pho

to C

red

it: E

van

Sem

on

/ V

ISIT

DE

NV

ER

Pho

to C

red

it: R

ich

Gra

nt


Your taste buds will be tantalized by a delicious three-course meal, featuring the best of Denver cuisine, and your soul will be uplifted by the funk and groovy tunes of Kool & The Gang.

Formed in the mid-60s, Kool & The Gang have performed continuously for the past 45 years, longer than any R&B group in history. Their chart-topping hits include “Get Down On It,” “Fresh,” “Cherish,” and the universally known song, “Celebration.”

Celebrate Good Times, Come On!Join us for an unforgettable Gala Dinner

with Kool & The Gang!

Tickets are limited!

Please visit the ticket counter in the registration area to purchase your tickets today (US$50 for registered delegates; US$75 for guests).

Tuesday, September 8 » 20:00-23:00 » Colorado Convention Center

population scientists who have an in-terest in lung cancer. Dr. Reck and Dr. Wakelee note that including topics of interest for these new member groups in WCLCs and the Journal of Thoracic Oncology is a fi rst step toward engaging them in the Society.

Many of the new Board members also emphasized the need to attract younger clinicians and scientists. “The future leaders in lung cancer will be among these individuals, and I think it is important to have them involved in IASLC from as early in their careers as possible, so that they feel that IASLC is their natural ‘home,’” says Dr. Boyer.

Reaching more members around the globe is also important. Dr. Boyer says he would like to encourage more mem-bers from Latin America and Asia. Dr. Satouchi adds, “I would like to make every effort to eliminate the barriers to minority IASLC members, includ-ing those from non-English speaking countries, younger researchers, and fe-male researchers.”

Targeting Younger Investigators Offering programs for younger in-

vestigators also emerged as an im-portant issue for IASLC to address. Dr. Harpole suggests establishing a database of international mentors for young investigators, especially given the lack of proper mentors in lung can-cer at many institutions.

“IASLC has a tremendous untapped resource of successful, senior investi-gators with nearly infi nite experience navigating career hurdles (often against the odds),” he says. He suggests an in-ternational database that would allow the matching of young scientists with

senior ones who have similar interests. Dr. Wakelee also suggests programs

for younger investigators, including an investigator in training program and an international “observership” pro-gram. She describes the investigator-in-training program as a series of webinars tailored to trainees that could be viewed in “lung cancer interest groups” in training programs.

“This would be a series over several weeks to expand multidisciplinary lung cancer knowledge and increase aware-ness of opportunities in lung cancer research along with awareness of the benefi ts of IASLC membership,” she explains.

The international observership pro-gram she envisions would enable prac-ticing physician researchers to spend 2-4 weeks in a foreign program. She proposes that this program should allow both parties to serve as a host, allowing researchers in developing programs to learn new strategies for success and giv-ing established researchers the oppor-tunity to better appreciate challenges faced internationally. “A mutual under-standing could lead to increased global collaborations,” she says.

Expanding Educational ActivitiesMany new Board members share a

goal of expanding educational activi-ties, especially across various regions, and capitalizing on its strongest educa-tional event, the WCLC.

“The now-annual WCLC is the pre-mier global lung cancer focused meet-ing; however, it remains a challenge for many investigators to attend,” says Dr. Wakelee. “Expansion of more regional meetings such as the Best of WCLC program should be a priority.”

She adds that IASLC could help fund such programs in developing nations.

Dr. Pirker agrees, noting that he hopes to work with colleagues to establish regular Best of WCLC meetings in Central and Eastern Europe.

Another way to extend the reach of education is through the IASLC website, and Dr. Ikeda would like to enhance the website by creating a so-phisticated e-library, consisting of mul-timedia educational activities. His goal is for the website to “become a more powerful tool for improving the ex-change of knowledge and techniques between members, particularly experts and practicing lung cancer specialists.”

Dr. Scagliotti echoes all these thoughts: “The Society should take specifi c actions (dedicated educational opportunities and workshops) for those emerging countries or geographic areas where tailored educational approaches are needed.”

Global Initiatives to Facilitate Research

Some new Board members envision global initiatives that will enable IASLC to facilitate lung cancer research. Dr. Harpole believes IASLC should estab-lish a task force to address the diffi culty in accruing patients to biomarker-driv-en trials because of the low incidence of mutations and rearrangements. This

task force could help streamline the process of patient screening for future trials of molecularly targeted agents. He also proposes the development of international translational research collaboration teams. He says, “Lung cancer research is a team sport, and we need a mechanism to identify teams around the globe with similar areas of investigation to join forces as opposed to competing for scarce grant dollars.” He adds that a searchable database of scientifi c expertise and specifi c labora-tory interests would be valuable in nur-turing collaborative grant applications.

In addition, Dr. Reck would like IASLC to develop a standardized ap-proach for the assessment of effi cacy of immunotherapies, whereas Dr. Satou-chi believes that a biobank and an in-ternational molecular database for lung cancer would be important resources.

“IASLC has worked hard over recent years to establish itself as the premier global group dedicated to understand-ing and eliminating lung cancer and other thoracic malignancies,” says Dr. Boyer. Armed with their goals and vi-sions, the new Board members are poised to overcome challenges, achieve success with new and continuing ini-tiatives, and help shape the future of IASLC.

IASLC Board Members Continued from page 10

Children Under 7 Years in Nigeria”Mini Oral 11: Tobacco Control and PreventionMonday, September 7; 16:45-18:15Rooms 601 + 603

Emmanuel OdiaseNigerian Cancer Society, Nigeria“One-Stop Counselling, Social Support & Stop Smoking Aids Helps Smokers Quit”Poster Session 1 Monday, September 7; 9:30-16:30Exhibit Hall B + C

Cristina PerezNational Cancer Institute of Brazil, Brazil“Prevalence Use of Others Tobacco Products: Findings from the ITC Brazil Survey”

Mini Oral 11: Tobacco Control and PreventionMonday, September 7; 16:45-18:15Rooms 601 + 603

Malcolm TagbarhaUniversity of Abuja, Nigeria“The Risk of Lung Cancer among Women Who Start Smoking as Teenagers”Poster Session 2 Tuesday, September 8; 9:30-16:30 Exhibit Hall (B + C)

Qi WangThe Second Affi liated Hospital of Dalian Medical University, China“An in Vitro Biomimetic Multi-Organ Microfl uidic Chip System to Test Lung Cancer Metastasis”Mini Oral 22: New TechnologyTuesday, September 8; 16:45-18:15Rooms 205 + 207

Scholarships and Awards Continued from page 6

Visit the IASLC Booth#3715

Learn about the world of member benefits

of IASLC membership, including

Journal of Thoracic Oncology

Obtain complimentary copies of reference

cards for the newly proposed IASLC

Staging System and the new WHO

Pathology Classification

Receive a complimentary copy of the

IASLC Atlas of ALK Testing in Lung Cancer,

a valuable resource for pathologists,

laboratory scientists, and practicing

physicians

Buy the comprehensive textbook,

IASLC Multidisciplinary Approach to

Thoracic Oncology, at a greatly

reduced price

Complete your conference evaluation and

obtain your CME certificate

Find out more about the 2016 WCLC, to be

held in Vienna, Austria, December 4-7, 2016

Stop by the IASLC Booth for more information on a variety of topics.

IASLC The only international

association solely dedicated to lung cancer research

and treatment

16th world conference on lung cancer † sunday, september 6 ... · i am supposed to say,...

Documents